- Gounder Gives Lowdown on Ebola, Peptides, and Colorectal Screenings
- ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
- ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
- 6 dental technology updates in May
- From clinician to leader: Building confidence, capability and leadership in dentistry
- Operationalizing AI at scale: A practical framework for enterprise-scale success
- 3 key stats on the orthodontist workforce
- Meet the COOs of 10 specialty DSOs
- Data, cross-training, and pipeline development: How health systems are rethinking OR staffing
- How top health systems are redefining the digital patient experience
- ‘The most significant change in 20 years’: Cancer centers prepare for daraxonrasib demand
- A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
- Budget-Strapped Montana Will Stress-Test Trump’s Medicaid Work Rules
- How CEOs actually use hospital rankings — and when they don’t
- What OU Health’s founding CEO learned building a new health system
- Arkansas hospital CEO to step down after 11 years for new role
- The behavioral health workforce pipeline: Where it stands and where it’s headed
- 6 major investments in youth behavioral health
- Coalition for Health AI unveils governance playbook for systems
- 66 health systems ranked by long-term debt
- UnitedHealthcare drops some prior auth requirements for cardiology, orthopedic services
- 8 No Surprises Act shake-ups physicians need to know
- The ASC independence playbook: 3 leaders’ thoughts
- Dr. Rahimah Maina opens new dental practice
- GWU offloaded its $450M physician group problem — why the industry watching
- The gastroenterologist pay gap
- Texas surgery center to double in size, add 2 ORs
- What dental leaders told us in May
- Climate Change: Statement on Proposed Rescission of Climate-Related Disclosure Rules
- Kenyan Court Blocks Trump's Plan To Quarantine Ebola Patients
- What’s going on at the FTC? 3 notes for ASC leaders
- 8 DSOs making headlines
- The physician noncompete battle in 5 key figures
- The physician red flags that can predict a bad ASC partner
- Patient death draws renewed CMS scrutiny at HCA’s Mission Hospital
- Nearly 70% of US counties lack a GI: 13 concerning workforce stats
- Statement of Commissioner Mark T. Uyeda on the Rescission of Climate-Related Disclosure Rules
- A new behavioral health profession is born
- Keynote Remarks at the 2026 Reagan National Economic Forum
- Statement on Proposing Release for Rescission of Climate-Related Disclosure Rules
- Dentists’ pay climbed the most in these 10 states
- Mental Health Disorders Now No. 1 Cause of Disability Worldwide
- Massachusetts AG sues UnitedHealthcare over alleged Medicaid fraud
- UnitedHealthcare to nix nearly two thirds of pediatric prior auths
- Industry Voices—Patients are building a new healthcare system. The industry is finally catching up
- Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
- Study: LA Canine Outbreak Caused By Low Vaccination Rates, Crowded Boarding
- Ocrelizumab Effective In Slowing Progressive MS, Trial Shows
- Long COVID Might Be Twice As Common As Previously Thought
- In Vaccine-Skeptical California County, A Potential Playbook To Contain Measles
- Heavy Drinking Harms College Students' Brain Power, Study Finds
- A Trump Stronghold Grapples With Health Risks of ICE Detention Sites
- After Her Bout of Amnesia, a $59,000 Billing Dispute Wouldn’t Go Away
- Pharma urged to modernize patient support as young adult cancer rates rise
- Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties
- MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
- Aetna to launch ‘on demand’ virtual mental health services in 2027
- U of Connecticut dental school reappoints dean for 2nd term
- Michigan dentist charged with Medicaid fraud
- Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
- Acadia in the headlines: 6 things to know
- 26 behavioral health executive moves to know
- AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
- Advocate Health grows Q1 revenue by 10.8% amid higher volumes, greater efficiency
- Behavioral health hospital operator to pay $32M in Medicare fraud settlement
- Bangladesh Measles Surge Kills 500+ Children; Vaccine Delays Blamed
- Care navigation startup Garner Health banks $100M series E at $2.74B valuation
- HCA bolsters workforce pipeline with healthcare professional college acquisition
- Plant-Based Diet May Cut Obesity Risk For Women In Menopause
- Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
- Penn Medicine, K Health partner to deploy AI clinical agents
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CMS finalizes changes to No Surprises Act dispute resolution process
- Smartwatch App Accurately Detects Major Epileptic Seizures
- Racial Gap Exists For Asthma Inhaler Use
- New Colon Cancer Screening Guidelines Add Blood And At-Home Tests
- Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
- CVS expands partnership with Salesforce for greater call center personalization
- Nurse Convicted In Patient's Death Turns Fatal Drug Error Into Cautionary Tale
- Wearable Ultrasound Patch Monitors High-Risk Pregnancies In Real Time
- In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
- Listen to the Latest ‘KFF Health News Minute’
- Teladoc Health inks partnership with Walmart to expand virtual care services
- PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion
- Kaléo speaks up on allergy awareness to amplify patient stories
- Privacy and PetShops: Remarks at the Regulatory PETshop Series: Cryptographic Technologies and Financial Services Regulation
- NYC Health + Hospitals adds 2nd behavioral health housing site
- Mindfulness isn’t a perk anymore — it’s a workforce strategy
- With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
- Hospitals again ask FTC, DOJ for exemption from expanded premerger notification filings
- Coalition for Health AI unveils governance playbooks for responsible AI adoption
- Amazon taps Roy Schoenberg to lead healthcare business as Neil Lindsay plans to step down
- Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
- U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy
- CAT on a Hot Tin Roof
- GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers
- GoodRx launches subscription program for low-cost generic medications, telehealth services
- George Washington University locks deal to hand off debt-ridden physician practice to UHS
- Humana invests $83M in new Florida pharmacy distribution center
- As J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey
- ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
- An insider’s look at LillyDirect
- GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
- Weight-Loss Program Helps Women Battling Breast Cancer
- Younger U.S. Women of Color Face Rising Breast Cancer Deaths
- High Fitness Doesn’t Raise A-fib Risk In Young Men, Study Finds
- Cheaper, Alternative Health Plans Are Having A Moment, But Critics Urge Caution
- Ultrafine Wildfire Smoke Particles May Pose Serious Health Risks
- Montana Hurries To Adopt Trump’s Medicaid Work Rules Amid Budget Woes
- Readers Address Drugged Driving, Suicide Prevention, Worker Shortages
- Nurse Convicted in Patient’s Death Turns Fatal Drug Error Into a Cautionary Tale
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
- FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
- Eli Lilly wins argument over Noom’s GLP-1 dosing claims
- Remarks at the Stanford Rock Center for Corporate Governance
- Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
- Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
- JD Power: Cost pressures worsen member experience with commercial plans
- Trump Admin Bars Key U.S. Researchers From Global Virus Response Talk
- Listen to the Latest ‘KFF Health News Minute’
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
- Everyone Has A Family Doc, But Can You Get An Appointment?
- Many U.S. College Students With Psychosis Are Not Receiving Treatment
- Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids
- Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds
- Dust Yields Clues to Viral Outbreaks, Study Finds
- 3 Medical Routines That Older People May Not Need
- Acting NIAID Chief Steps Down Amid Ebola, Hantavirus Concerns
- Sunscreen Confusion Puts More Americans At Risk For Melanoma
- 1 In 10 U.S. Surgeons Quit Practice, Study Warns Of Shortage
- Video Game Can Detect Depression In Minutes, Study Says
- Quitting Smoking Might Lower Your Dementia Risk
- Severe Asthma Often Comes With Other Serious Health Problems
- Efforts To Understand The Nation's Drugged Driving Problem Stall Under Trump
- RFK Jr. Fires Two Leaders Of Major U.S. Health Task Force
- Common Food Preservatives Linked to Major Heart Problems
- Migraine With Aura Linked To Middle-Age Stroke Risk
- Nicotine Vapes Triple Smokers' Odds Of Quitting Tobacco
- Fatty Liver Disease Increases Heart Attack Risk, Study Says
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- The failure of the ‘usual suspects’ approach to life science recruitment
- The failure of the ‘usual suspects’ approach to life science recruitment
- Statement on Novel Exchange-Traded Funds (ETFs)
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
I have promoted OTC status for Ivermectin since early 2022, when I pointed out that raging social media warriors were wrong to demand hospitals include it in protocols. The large meta-study available at the time did not include data from late (hospital) treatment. However, it did demonstrate that
... early treatment allowed most to avoid the hospital entirely.
In addition to early treatment success, people know their own symptoms and results best. When an endemic disease has safe treatment, it’s common sense to self-treat and avoid hospitals.
MedPage Today reviews states doing just that.
https://www.medpagetoday.com/special-reports/features/116436
These States Now Allow OTC Ivermectin, and More May Follow
— Four have passed new laws, and at least nine have legislation in the works
by Rachael Robertson | July 9, 2025
A handful of states have passed legislation allowing ivermectin to be sold and purchased over-the-counter (OTC) -- and other state legislatures have their sights set on doing the same.
During the pandemic, rampant misinformation drew attention to the antiparasitic as a treatment for COVID, though research continues to show it is not effective against the disease.
Ivermectin tablets are FDA approved at specific doses for treating some parasitic worms, as are topical formulations for some skin conditions and head lice, but neither are FDA approved for preventing or treating COVID. Despite this, an increasing number of states are making it easier to get ivermectin and protecting pharmacists from lawsuits and discipline by licensing boards. None of the laws have information about dosing.
Currently four states -- Tennessee, Arkansas, Idaho, and Louisiana -- have passed OTC ivermectin laws.
In April 2022, Tennessee passed SB 2188/HB 2746, becoming the first state to make ivermectin available OTC. The legislation authorizes "ivermectin suitable for human use" to be sold or purchased OTC "without a prescription or consultation with a pharmacist or other healthcare professional." For 3 years, Tennessee was the only state to have OTC ivermectin.
Then on March 25 of this year, Arkansas passed SB 189, now Act 396. Weeks later, on April 14, Idaho passed similar OTC ivermectin legislation, SB 1211.
Louisiana SB 19, now Act 464, went into effect on June 20, making it the latest state to make ivermectin available OTC. This law specifies that a pharmacist can dispense ivermectin to adults "pursuant to a standing order issued by a healthcare professional with prescriptive authority" and requires the pharmacist to provide the patient with information on indications and contraindications as well as a screening risk assessment tool. For this service, the pharmacy may charge an administrative fee. Ralph Abraham, MD, the state's surgeon general, backed the bill.
In addition to these, other states have bills moving through their legislatures:
Texas
Just this week, 20 Texas House Republicans asked Gov. Greg Abbott (R) to add the reclassification of ivermectin as OTC -- under proposed HB 3219 -- to the agenda for a special session set to begin later this month. Some of these lawmakers have connected the issue to medical freedom.
New Hampshire
A bill with a unique two-fold approach, SB 119, was introduced in May, which lumps together ivermectin access with an unrelated Medicaid provision. The bill would allow pharmacists to follow a standing order from a physician, physician assistant, or advance practice registered nurse to dispense ivermectin alongside an information sheet on side effects. Also included are various protections against disciplinary action for these healthcare professionals.
The paired Medicaid provision "directs pharmacists to dispense brand name drugs to Medicaid beneficiaries when the brand name drug is on the department of health and human services preferred drug list."
North Carolina
The Ivermectin Access Act, or HB 618, was proposed in April 2025. This legislation would direct the state health director "to issue a statewide standing order to allow pharmacists to dispense ivermectin without prescription" as well as "providing immunity from civil or criminal liability" for both the director and any pharmacist who dispenses ivermectin.
Pennsylvania
Also in April, a lawmaker proposed SB 601, which would amend the state's Pharmacy Act to make ivermectin available OTC.
Georgia
In March, SB 366 was first proposed to amend parts of the Official Code of Georgia Annotated related to controlled substances and to pharmacists and pharmacies. This would "provide for ivermectin as an over-the-counter medication in this state" and "remove ivermectin from the definition of, exceptions to, and exemptions from dangerous drugs."
Alabama
A lawmaker brought forth HB 278 in February, which would "permit a physician, a physician assistant, or a certified registered nurse practitioner to give a pharmacist a standing order that has been approved by the State Board of Pharmacy to dispense ivermectin to individuals without a prescription." The standing order would involve a risk assessment protocol and a standardized information sheet.
It also has various disciplinary protections for pharmacists and forbids them from participating in "any program or accept anything of value that induces the healthcare provider or pharmacist to affirmatively commend or endorse the use of ivermectin to an individual or the public."
If passed, the legislation would take effect in October of this year.
West Virginia
SB 614 was also introduced in February. The bill would authorize pharmacists to dispense ivermectin without a prescription or consultation and protect them from liability from damages or licensing board discipline.
Missouri
SB 744, which would make both ivermectin and hydroxychloroquine available OTC, was introduced in February, though it has not made much progress. A similar bill, HB 2581, was proposed in January 2024, but never passed.
South Carolina
HB 3916, proposed in February, also aims to make both ivermectin and hydroxychloroquine available without prescription or consultation.
Axios's Ivermectin update couldn't be more biased, but hang in there: the good stuff is toward the end.
https://www.axios.com/local/phoenix/2026/02/02/ivermectin-over-the-counter-arizona-bill
Arizona bill would let people buy ivermectin without a prescription
Jessica Boehm, Kim Bojórquez | Feb. 2, 2026
Republicans in Arizona and nationwide are trying to make it easier to get ivermectin, the controversial anti-parasitic drug widely used to treat livestock but embraced by some as a treatment during the pandemic.
Why it matters: Ivermectin was promoted largely by conservatives as a "miracle" drug amid the COVID-19 pandemic, despite multiple medical studies that found it isn't effective at treating the novel coronavirus, and repeated warnings from leading medical institutions outside of FDA-approved use. Still, it has persisted as an alternative treatment for COVID.
The drug is approved for human use to treat parasitic worms and conditions such as head lice and rosacea, per the FDA.
State of play: Arizona State Rep. Nick Kupper (R- Surprise) sponsored a bill to make ivermectin that's formulated for human use available over the counter without a prescription or medical consultation.
The measure has not yet been scheduled for a hearing.
The intrigue: Kupper, who did not respond to Axios' interview request, told Arizona's Family he introduced the bill in response to constituent interest in the drug, and he dismissed health concerns.
"Think about how many energy drinks we drink every day. There's caffeine in coffee or vaping or smoking cigarettes. … These are all things that you don't need a prescription to get," Kupper told Arizona's Family.
The other side: Doctors and toxicologists, including the American Medical Association, American Pharmacists Association and American Society of Health-System Pharmacists, have widely cautioned against ivermectin use.
During the pandemic, the Banner Poison and Drug Information Center in Phoenix and Arizona Poison and Drug Information Center in Tucson said they received several calls concerning ivermectin exposure.
"Higher doses can cause significant illness in humans," Daniel Brooks, then the medical director of the Banner Poison and Drug Information Center, said in a 2021 statement.
Reality check: Will Humble, executive director for the Arizona Public Health Association, told Axios the bill is "performative."If it reaches Democratic Gov. Katie Hobbs' desk, she'll almost certainly veto it, he said.
Even so, it's unlikely that national chain pharmacies would stock the drug — even if given state approval — because of federal legal and licensure risks.Plus, people who really want ivermectin can already get it at many of Arizona's livestock supply stores without a prescription, because it's widely used for deworming horses.
Zoom out: At least five states have already legalized ivermectin sales without a prescription: Texas, Tennessee, Arkansas, Idaho and Louisiana.Republican Utah state Rep. Trevor Lee introduced a bill in his state, telling Axios it would expand medical freedom and align with Health and Human Services Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















